TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00188344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pneumatic dilatation
Description: The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours.
Study: NCT00754481

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature \< 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
Study: NCT00290199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter
Description: Foley catheter placed through cervix for cervical ripening
Study: NCT00868348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml infiltration 4 ml intraarticular bolus injection of placebo
Study: NCT00255970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA
Description: Demineralized Freeze Dried Allograft bone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regenafil
Description: Demineralized Freeze Dried Bone in a porcine gel carrier

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenafil
Description: Demineralized Freeze Dried Bone in a porcine gel carrier
Study: NCT02817971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced feedback
Description: Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard feedback
Description: Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
Study: NCT01380379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills and self-defense training
Description: 8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
Study: NCT01353040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-6003
Description: Single intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous administration
Study: NCT03599128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 43.3 mg hydrolyzed green coffee extract
Description: Reconstituted in water and given to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 86.6 mg hydrolyzed green coffee extract
Description: Reconstituted in water and given to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 173 mg hydrolyzed green coffee extract
Description: Reconstituted in water and given to subjects

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reconstituted in water and given to subjects
Study: NCT01766960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat breakfast will be administered to induce gall bladder emptying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat breakfast will be administered to induce gall bladder emptying.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Five milligrams of intravenous morphine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Five milligrams of intravenous morphine will be administered.
Study: NCT00503594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate and temozolomide
Description: Methotrexate and temozolomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate , procarbazine ,vincristine ,cytarabine
Description: Methotrexate , procarbazine ,vincristine ,cytarabine
Study: NCT00102011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: annual screening
Description: Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fecal occult blood test
Description: Participants undergo a baseline fecal occult blood test (FOBT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fecal occult blood test
Description: Participants undergo a baseline fecal occult blood test (FOBT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening colonoscopy
Description: Patients undergo baseline screening colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening colonoscopy
Description: Patients undergo baseline screening colonoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard follow-up care
Description: Standard care
Study: NCT00413647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardioPET
Study: NCT01708070

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Asthma self-management
Description: Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma self-management
Description: Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
Study: NCT02800889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone
Description: Pixantrone
Study: NCT00670436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel eluting PTCA balloon catheter (SeQuent Please)
Description: paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel eluting Taxus stent (Boston Scientific)
Description: paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
Study: NCT00546767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mail and Live Phone
Description: This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Description: In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Computer Kiosk
Description: Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Evaluation Instruments
Description: Evaluation methods typically used in clinical trials
Study: NCT03045445

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Double Low-Dose protocol CT
Description: Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol CT
Description: standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
Study: NCT04429906

Intervention type: DEVICE
Intervention: Huami smart wearable device
Description: Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group.
Study: NCT03791242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cpap and ketogenic diet
Description: Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cpap and ketogenic diet
Description: Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
Study: NCT04714242

Intervention type: DRUG
Intervention: Ranibizumab Injection
Description: Three monthly intravitreal injections of Ranibizumab
Study: NCT03317470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic needs survey
Description: -11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic needs survey
Description: -11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Navigator
Description: * The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~* The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up survey
Description: -5 questions about the acceptability of the basic needs survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up survey
Description: -5 questions about the acceptability of the basic needs survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up survey (phase II participants only)
Description: -7 questions about the effectiveness of the life navigator
Study: NCT01687075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR8 a drug eluting coronary stent
Description: a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
Study: NCT00714675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: 1 unit of 10 g L-Citrulline, 1 time on morning during 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: 1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
Study: NCT03715842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tub shaped design
Description: The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inlay shaped design
Description: The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
Study: NCT01258244

Intervention type: OTHER
Intervention: Audiovisual Feedback
Description: EMTs will get audiovisual feedback on CPR technique during CPR
Study: NCT00649883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Trivalent Inactivated vaccines Novartis
Description: Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Trivalent Inactivated vaccines
Description: Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
Study: NCT01182402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliance monitoring with electronic device
Description: Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
Study: NCT04419610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRV027
Description: peptide for infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: placebo comparator for infusion
Study: NCT03638154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GF+GMSCs carried on β TCP
Description: surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: β TCP bone substitute only
Description: surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
Study: NCT02878538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone
Description: Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phase
Description: Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
Study: NCT00692484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: Povidone iodine scrub and paint. Administer topically.
Study: NCT03584828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele Cardiac Rehabilitation
Description: A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program.
Study: NCT01490450

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-945429
Description: Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Study: NCT03366688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBI306
Description: Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
Study: NCT04363528

Intervention type: OTHER
Group type: OTHER
Intervention: Doppler Echo
Description: 2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart